Back to top
more

Cue Biopharma (CUE)

(Delayed Data from NSDQ)

$1.65 USD

1.65
790,501

-0.06 (-3.51%)

Updated Nov 6, 2024 04:00 PM ET

Pre-Market: $1.65 0.00 (0.00%) 9:26 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (89 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks News

Strength Seen in Cue Biopharma, Inc. (CUE): Can Its 6.4% Jump Turn into More Strength?

Cue Biopharma, Inc. (CUE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Vascular Biogenics (VBLT) Reports Q4 Loss, Lags Revenue Estimates

Vascular Biogenics (VBLT) delivered earnings and revenue surprises of -50% and 2%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

ChromaDex (CDXC) Reports Q4 Loss, Lags Revenue Estimates

ChromaDex (CDXC) delivered earnings and revenue surprises of 27.27% and 3.59%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

YmAbs Therapeutics, Inc. (YMAB) Reports Q4 Loss, Misses Revenue Estimates

YmAbs Therapeutics, Inc. (YMAB) delivered earnings and revenue surprises of -19.72% and 7.46%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Bellus Health (BLU) Reports Q4 Loss, Lags Revenue Estimates

Bellus (BLU) delivered earnings and revenue surprises of 35.71% and 60%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Cue Biopharma, Inc. (CUE) Stock Jumps 6.5%: Will It Continue to Soar?

Cue Biopharma, Inc. (CUE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Cue Biopharma, Inc. (CUE) Soars 8.3%: Is Further Upside Left in the Stock?

Cue Biopharma, Inc. (CUE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Analysts Estimate Cue Biopharma, Inc. (CUE) to Report a Decline in Earnings: What to Look Out for

Cue Biopharma, Inc. (CUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Cue Biopharma, Inc. (CUE) Q2 Earnings Expected to Decline

Cue Biopharma, Inc. (CUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Strength Seen in Cue Biopharma, Inc. (CUE): Can Its 27.7% Jump Turn into More Strength?

Cue Biopharma, Inc. (CUE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Do Options Traders Know Something About Cue Biopharma (CUE) Stock We Don't?

Investors need to pay close attention to Cue Biopharma (CUE) stock based on the movements in the options market lately.

Cue Biopharma (CUE) Catches Eye: Stock Jumps 5.2%

Cue Biopharma (CUE) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

Cue Biopharma, Inc. (CUE) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

Cue Biopharma, Inc. (CUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Cue Biopharma, Inc. (CUE) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

Cue Biopharma, Inc. (CUE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Cue Biopharma, Inc. (CUE) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

Cue Biopharma, Inc. (CUE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks.com featured highlights include: ThermoGenesis, 21Vianet, Livongo Health, Cue Biopharma and Sharps Compliance

Zacks.com featured highlights include: ThermoGenesis, 21Vianet, Livongo Health, Cue Biopharma and Sharps Compliance

The Zacks Analyst Blog Highlights: Cue Biopharma, PJT Partners, Avenue Therapeutics, SpartanNash and Gaia

The Zacks Analyst Blog Highlights: Cue Biopharma, PJT Partners, Avenue Therapeutics, SpartanNash and Gaia

Nalak Das headshot

5 Stocks With Recent Price Strength to Tap Market Rally

Investors target stocks that are witnessing a bullish run. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.

Nalak Das headshot

5 Top Small-Cap Stocks Braving Coronavirus Bloodbath

A handful of small-cap stocks have skyrocketed defying the coronavirus-induced market mayhem and extreme volatility.

Should You Buy Cue Biopharma (CUE) Ahead of Earnings

Cue Biopharma (CUE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Cue Biopharma, Inc. (CUE) Expected to Beat Earnings Estimates: Should You Buy?

Cue Biopharma, Inc. (CUE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks.com featured highlights include: Farmers National, Independent Bank, First Financial Bankshares, HarborOne and Cue Biopharma

Zacks.com featured highlights include: Farmers National, Independent Bank, First Financial Bankshares, HarborOne and Cue Biopharma

Shrabana Mukherjee headshot

5 Stocks to Make the Most of New Analyst Coverage

Increased analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.

Zacks.com featured highlights include: Independent Bank, HarborOne, Horizon Technology Finance and Cue Biopharma

Zacks.com featured highlights include: Independent Bank, HarborOne, Horizon Technology Finance and Cue Biopharma

Shrabana Mukherjee headshot

4 Stocks in Focus as New Analysts Show Interest

Increased analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.